--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-205066" form_type: "8-K" ticker: "WVE" cik: "0001631574" company_name: "Wave Life Sciences Ltd." filed_at: "2023-08-07T23:59:59+00:00" generated_at: "2026-06-12T04:21:11.916814+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.3 confidence: "high" source: SEC EDGAR --- # Wave Life Sciences shareholders approve 6.5M share increase to equity plan and 2M to ESPP ## Summary - Shareholders approved amendment to 2021 Equity Incentive Plan adding 6,500,000 authorized shares. - Shareholders approved amendment to 2019 ESPP adding 2,000,000 authorized shares. - All nine director nominees re-elected; highest votes against were 9.3M for Ken Takanashi. - KPMG reappointed as auditor (99.9% for); advisory say-on-pay approved with 98.5% of votes cast. - Over 84% quorum; 83.5 million of 98.98 million shares voted at annual meeting. ## SEC filing metadata - accession: 0001193125-23-205066 - form_type: 8-K - ticker: WVE - cik: 0001631574 - company_name: Wave Life Sciences Ltd. - filed_at: 2023-08-07T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.3 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/d539015d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-205066 - JSON: https://secwatch.observer/filing/0001193125-23-205066.json - Plain text: https://secwatch.observer/filing/0001193125-23-205066.txt ## Key facts - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved the Company’s payment of cash and equity-based compensation to the Company’s non-employee directors for their service on the Board of Directors and its committees at the 2023-08-01 meeting. - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved the Company’s payment of cash and equity-based compensation to the Company’s non-employee directors for their service on the Board of Directors and its committees evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved the amendment to the Company’s 2019 Employee Share Purchase Plan at the 2023-08-01 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved the amendment to the Company’s 2019 Employee Share Purchase Plan evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders re-elected nine of the Company’s existing directors to the Board of Directors for a term ending on the Company’s 2024 Annual General Meeting of Shareholders and until his or her successor is duly elected and qualified at the 2023-08-01 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders re-elected nine of the Company’s existing directors to the Board of Directors for a term ending on the Company’s 2024 Annual General Meeting of Shareholders and until his or her successor is duly elected and qualified evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved the amendment to the Company’s 2021 Equity Incentive Plan, as amended at the 2023-08-01 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved the amendment to the Company’s 2021 Equity Incentive Plan, as amended evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers at the 2023-08-01 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved the re-appointment of KPMG LLP to serve as the Company’s independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for serv at the 2023-08-01 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved the re-appointment of KPMG LLP to serve as the Company’s independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of the Company’s 2024 Annual General Meeting of Shareholders evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm - Shareholder Votes Wave Life Sciences Ltd. shareholders approved Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company at the 2023-08-01 meeting. - Outcome: passed - Meeting: 2023-08-01 source text: Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/0001193125-23-205066-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.